IMKELDI
Growthimatinib oral
NDAORALSOLUTION
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
IMKELDI (imatinib oral) is protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the philadelphia chromosome abnormality in cml. First approved in 2024.
Drug data last refreshed 12h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMKELDI is an oral solution formulation of imatinib, a protein-tyrosine kinase inhibitor targeting BCR-ABL and c-Kit mutations. It is indicated for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) by blocking abnormal kinase signaling that drives proliferation. The solution formulation may improve bioavailability and patient convenience compared to tablet formulations.
Growth13.5 years to LOE
Early-stage growth product with recent FDA approval; commercial team expansion likely as market penetration builds and indication portfolio expands.
Mechanism of Action
protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IMKELDI positions you in a growth-stage oncology asset with extended patent protection through 2040; limited current job posting activity suggests a smaller, focused team being built for market penetration. This is an opportunity to shape commercial strategy for a reformulated established therapy in a competitive oncology landscape.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.